Editas Medicine

EDIT

EDIT
Editas Medicine Stock Quote
$20.39 -$0.10 -0.5%
BATS BZX Real Time Price as of November 11, 2019, 4:00 p.m. EST View Interactive EDIT Charts

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

News & Analysis: Editas Medicine

The Fool has written over 100 articles on Editas Medicine.

All

Market Moves

Earnings



Editas Medicine Remains on Track

With a new CEO in place and a groundbreaking "in vivo" dosing study approaching, the gene-editing leader is rightly excited for the future.




Is Editas Medicine a Buy?

High risk? Definitely. But this small biotech also has the potential for high returns over the long run.






Interactive Chart